Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B

[Guest guest]

http://www.cghjournal.org/article/PIIS1542356510012279/abstract?rss=yes

Clinical Gastroenterology and Hepatology

Volume 9, Issue 3 , Pages 274-276.e1, March 2011

Schiff ER et al. - Chronic hepatitis B patients with advanced fibrosis or

cirrhosis demonstrated histologic improvement and reversal of fibrosis and

cirrhosis after long-term treatment with entecavir.

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or

Cirrhosis in Patients With Chronic Hepatitis B

Affiliations

University of Miami Hospital and Clinics, Miami, Florida

Reprint requests Address requests for reprints to: Eugene R. Schiff, MD, Center

for Liver Diseases, University of Miami, 1500 NW 12th Avenue, Suite 1011, East

Tower, Miami, Florida 33136; fax: (305) 243–3877

Background & Aims

Long-term treatment with entecavir resulted in durable virologic suppression and

continued histologic improvement in nucleoside-naive chronic hepatitis B

patients. Patients with advanced fibrosis or cirrhosis, who received long-term

entecavir treatment, were evaluated for improvement in liver histology.

Methods

The study included a subset of patients from phase III and long-term rollover

studies, who received entecavir for at least 3 years, had advanced fibrosis or

cirrhosis, and evaluable biopsies at baseline and after long-term treatment.

Results

Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis

score, ≥4). After approximately 6 years of cumulative entecavir therapy

(range, 267–297 wk), all 10 patients showed improvement in liver histology and

Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and

Knodell necroinflammatory scores were −2.2 and −7.6, respectively. A

reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients

who had cirrhosis at baseline.

Conclusions

Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated

histologic improvement and reversal of fibrosis and cirrhosis after long-term

treatment with entecavir.

[Guest guest]

http://www.cghjournal.org/article/PIIS1542356510012279/abstract?rss=yes

Clinical Gastroenterology and Hepatology

Volume 9, Issue 3 , Pages 274-276.e1, March 2011

Schiff ER et al. - Chronic hepatitis B patients with advanced fibrosis or

cirrhosis demonstrated histologic improvement and reversal of fibrosis and

cirrhosis after long-term treatment with entecavir.

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or

Cirrhosis in Patients With Chronic Hepatitis B

Affiliations

University of Miami Hospital and Clinics, Miami, Florida

Reprint requests Address requests for reprints to: Eugene R. Schiff, MD, Center

for Liver Diseases, University of Miami, 1500 NW 12th Avenue, Suite 1011, East

Tower, Miami, Florida 33136; fax: (305) 243–3877

Background & Aims

Long-term treatment with entecavir resulted in durable virologic suppression and

continued histologic improvement in nucleoside-naive chronic hepatitis B

patients. Patients with advanced fibrosis or cirrhosis, who received long-term

entecavir treatment, were evaluated for improvement in liver histology.

Methods

The study included a subset of patients from phase III and long-term rollover

studies, who received entecavir for at least 3 years, had advanced fibrosis or

cirrhosis, and evaluable biopsies at baseline and after long-term treatment.

Results

Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis

score, ≥4). After approximately 6 years of cumulative entecavir therapy

(range, 267–297 wk), all 10 patients showed improvement in liver histology and

Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and

Knodell necroinflammatory scores were −2.2 and −7.6, respectively. A

reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients

who had cirrhosis at baseline.

Conclusions

Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated

histologic improvement and reversal of fibrosis and cirrhosis after long-term

treatment with entecavir.